Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab and Lenalidomide in Previously Untreated Follicular Lymphoma
NCT06112847Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab and lenalidomide in follicular lymphoma (FL), sponsored by City of Hope. Primary endpoint: Complete Response Rate up to 2 years. Started Jan 2024; status: active, not recruiting.
02
Drugs
epcoritamablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06112847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112847.